Los Angeles Addiction Treatment & Clinical Research at UCLA SARx

Social Networks and Drug Cues Presentation Abstract Online

noreply@blogger.com (UCLA SARx) — Mon, 07 May 2012 20:30:00 +0000

Our abstract from the APA research meeting is now available online along with all of the other APA research abstracts at the APA meeting website. A copy of the abstract is below! Enjoy!

Online Social Networking Sites are Drug Use Triggers among Adolescents in Substance Abuse Treatment

Chair: David Tran B.A.; Author(s): Keith Heinzerling, M.D., M.P.H.; James McCracken, M.D.

Summary:

OBJECTIVES: Exposure to environmental cues previously associated with drug use (“people, places, and things”) is a common precipitant of drug relapse among persons receiving treatment for drug addiction. Social networks also influence substance use and this effect may be mediated via environmental cues. Use of online social networking sites has increased dramatically especially among youth. Yet the extent to which online social networking may be a source of exposure to drug
cues (“people, places, things”) among youth in substance abuse treatment is not known. This study surveyed youth in substance abuse treatment on their use of online social networking and potential exposure to drug cues.

METHODS: A 20‑question questionnaire was administered to 37 youth, aged 12 to 18, who are receiving substance abuse treatment at an adolescent treatment center in East LA. The proportion of youth who report use of online social networking sites, as well as, the proportion who report exposure to drug‑related cues was calculated. Demographics of youth who do and do not report use of social networking sites and, among those who do, exposure to drug‑cues will be compared via t‑tests and chi square analysis.

RESULTS: (1) On youth in substance abuse treatment: 92% use online social networking sites, with a majority using Facebook. 89% report marijuana as his/her drug of choice. (2) On level of exposure to drug‑related information from use of social networking sites: 88% of boys and 100% of girls reported that his/her friends on Facebook/MySpace/Twitter use drugs (p = 0.145). 94% of adolescents reported his/her friends post on drug‑related content whereas 22% reported his/her friends post on recovery‑related content (p = 0). 77% of girls and 53% of boys report that something on Facebook/MySpace/Twitter made them feel like they wanted to use drugs (p = 0.169).

CONCLUSION: A majority of youth in treatment use social networking sites. Their drug of choice is marijuana. Drug cues via online social networking exist and influence youth to use drug while in treatment. These results will be used to design an intervention to mitigate online risks to substance abuse treatment outcomes.

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

Picutres/video from today's presentation in HIV and Meth Addiction

noreply@blogger.com (UCLA SARx) — Thu, 03 May 2012 22:14:00 +0000

For info on today's presentation on HIV prevention and meth addiction- check out our Twitter feed (@UCLASARx) or our Facebook page (www.facebook.com/uclasarx).

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

Exposure to Drug-related ‘People, Places, and Things’ via Online Social Networking Sites among Adolescents in Substance Abuse Treatment

noreply@blogger.com (UCLA SARx) — Tue, 01 May 2012 00:42:00 +0000

UCLA Medical Student David Tran, working with UCLA SARx faculty member Dr. Keith Heinzerling, will be featured in a webinar at the APA meeting highlighting his research on Facebook and adolescents in substance abuse treatment!!! We are honored to have such great UCLA medical students! More details below:

New Research in Medicine and Mental Health Press Briefing at APA Annual Meeting and via Live Webinar

Arlington, VA (April 30, 2012) – More than 400 cutting edge “New Research” posters will be presented at the 2012 APA Annual meeting, and each year the Office of Communications and Public Affairs chooses a handful of important projects to highlight at the annual New Research Press Briefing. These presentations represent a cross section of the most interesting things happening in research, academia, military medicine and industry and are authored by doctors, professors, medical students and scientists from around the world.

At the press conference each author will briefly describe his or her research and its benefits to medicine and mental health and then will take questions from reporters in the room as well as reporters joining via the webinar. The event will be hosted by renowned psychiatrist Jeffrey Borenstein, M.D., Medical Director of Holliswood Hospital in New York City, host of the television show “Healthy Minds,” and chair of the APA Council on Communications.

The event will be held at the APA Annual Meeting in Philadelphia and available live via webinar Sunday May 6th, 11:30 am – 12:30 am Eastern Time. Any member of the press not attending the Annual Meeting is invited to join us live via webinar by registering at www2.gotomeeting.com/register/217936466<https://www2.gotomeeting.com/register/217936466>.

The briefing will highlight the following New Research Projects and authors

Abid Malik, M.D.

Could REM Sleep be a Biological Biomarker for Anxiety Disorders?

Lieutenant Commander Ralph Tuttle, M.D. US Navy

Effects of Antidepressants on Neuropsychological Function Related to Combat Performance

David Tran

Exposure to Drug-related ‘People, Places, and Things’ via Online Social Networking Sites among Adolescents in Substance Abuse Treatment

Ronit Dedesma, M.D.

Using an Electronic Medical Record (EMR) to improve Metabolic Monitoring for Patients on Antipsychotic Medicines: An Interdepartmental Interdisciplinary Quality Project

Janet Williams, Ph.D.

The Power of Expectation Bias

Umesh Vyas, M.D.

Treating Sleep Disorders has Positive Outcomes in Psychiatric Illness

Dinesh Mittal, M.D.

Stigma Experiences of Combat Veterans with PTSD from Iraq and Afghanistan Wars

Abstracts of each poster will be available on May 5th on the APA website at www.psychiatry.org/learn/2012-annual-meeting/scientific-sessions/2012-annual-meeting-publications<http://www.psychiatry.org/learn/2012-annual-meeting/scientific-sessions/2012-annual-meeting-publications>.

The American Psychiatric Association is a national medical specialty society whose physician members specialize in the diagnosis, treatment, prevention, and research of mental illnesses, including substance use disorders. Visit the APA at www.psychiatry.org<http://www.psychiatry.org> and www.HealthyMinds.org<http://www.healthyminds.org/>.

###

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

NEW UCLA SARx METH STUDY PUBLISHED

noreply@blogger.com (UCLA SARx) — Tue, 01 May 2012 00:11:00 +0000

New results posted on out METH page. Check them out.

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

Baseline Findings from the HPTN 061 BROTHERS Project: Participant Characteristics

noreply@blogger.com (UCLA SARx) — Fri, 20 Apr 2012 19:31:00 +0000

Dr. Shoptaw of UCLA SARx to give major presentation on research findings related to HIV prevention and methamphetamine in Los Angeles. Be there...

Details on our METH page!

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

Just say no?

noreply@blogger.com (UCLA SARx) — Thu, 12 Apr 2012 01:14:00 +0000

Patient satisfaction is important. Good medical care requires trust and a partnership between doctor and patient. But sometimes wanting to satisfy the patient too much can lead to harm. Case in point, just giving a patient the opioids they ask for may not be the right thing if they are opioid dependent. Check out this article from JAMA discussing the patient centered medical home and controlling prescription opioid abuse.

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

High Dose Opioids for Pain and Overdose Risk

noreply@blogger.com (UCLA SARx) — Wed, 11 Apr 2012 18:59:00 +0000

It seems almost everyone is now aware of the huge increase in overdoses on prescription medications, especially opioid pain medications. Studies show that the risk of overdose is highest for patients on the highest doses of opioids. While the dosing differs for each different opioid formulation,it is possible to compare doses for patients on different opioids by converting the dose of the opioid to the equivalent dose for morphine. For example, 30 mg of oxycodone is approximately equivalent to 45 mg of morphine. In particular, patients on doses higher than 100 mg a day morphine equivalent are at especially high risk of overdose-- almost 9 times the risk of overdose compared to patient taking less than 20 mg morphine equivalent a day in a recent study.

There are several free online tools that allow doctors (and patients for that matter) to estimate the equivalent dose in morphine that the patient is taking. We uses these regularly and take particular care with patients who are on doses above 100 mg a day morphine equivalents. While high doses like these may be appropriate, doctors and patients should also be aware of the increased risk of overdose with these high doses. Sometimes these patients have developed tolerance to the opioids and a period of detoxification is needed to allow them to again be effectively treated with lower, safer doses. If you are concerned this may be the case, contact us as we may be able to help.

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

New UCLA SARx study published on differences in meth use between men and women

noreply@blogger.com (UCLA SARx) — Mon, 02 Apr 2012 15:49:00 +0000

Check out our UCLA SARx METH PAGE for news about the results of a newly published study examining differences in meth use between men and women and the possible role of genetics in these differences.

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

Cocaine and amphetamine positive tests increase in the workplace.

noreply@blogger.com (UCLA SARx) — Tue, 20 Mar 2012 15:24:00 +0000

Check out our new entry on our Meth page with Dr. Shoptaw from UCLA SARx being quoted in the Orange County Register regarding increased use of cocaine and meth in the workplace.

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

Conference: Preventing HIV, Hepatitis, & Tuberculosis Among Substance-Using Populations

noreply@blogger.com (UCLA SARx) — Wed, 18 Jan 2012 19:20:00 +0000

SAVE THE DATE!

Presented by the UCLA Department of Family Medicine

MAKING CONNECTIONS

Thursday, June 21, 2012
8am to 5pm

The goal of the conference is to facilitate face-to-face exchanges on integrating HIV, viral hepatitis, and tuberculosis prevention services among substance-using populations.

Target audience includes public health leaders, treatment providers, prevention partners, policy-makers, executive directors, and program directors.

Food and parking will be provided.

The California Endowment
1000 North Alameda St.
Los Angeles, CA 90012

Funding for this conference was made possible in part by a cooperative agreement award #1U13PS003329-01 from the Centers for Disease Control and Prevention. Additional funding provided by the UCLA Department of Family Medicine and the Policy Core of the UCLA Center for HIV Identification, Prevention, and Treatment Services (5P30MH058107).

For more info, contact Uyen Kao at ukao@mednet.ucla.edu

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

Addiction Medicine Fellowship- Primary Care Doctors!!

noreply@blogger.com (UCLA SARx) — Thu, 12 Jan 2012 17:28:00 +0000

Are you a primary care doctor interested in Addiction Medicine, or do you know one? UCLA SARx has a NIH funded fellowship to train primary care doctors in Addiction Medicine. For more information or to apply go to:

http://fm.mednet.ucla.edu/CHPDP/training.asp

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

New UCLA SARx Meth Research Published

noreply@blogger.com (UCLA SARx) — Mon, 09 Jan 2012 19:04:00 +0000

Check out the latest on UCLA SARx meth research on the UCLA SARx Meth Page!

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

Check out the new METH section of our website

noreply@blogger.com (UCLA SARx) — Thu, 05 Jan 2012 16:54:00 +0000

Introducing the new METH section of the UCLA SARx website, with info on crystal meth addiction treatment and research.

Find the section at: http://meth.uclasarx.org/

Also- check out UCLA SARx's Dr Shoptaw who was quoted in a USA Today article on meth addiction! More info at:

http://meth.uclasarx.org/2012/01/meth-problems-continue-to-be-major-in.html

If you have questions or comments-- post below, e-mail us or send a message via http://twitter.com/uclasarx! We welcome your feedback! Thanks for tuning in.

UCLA SARx on Facebook

noreply@blogger.com (Maria Sipin) — Thu, 08 Dec 2011 20:04:00 +0000

Hello Facebook community! We are now on Facebook.

Vine Street Sarx likes

UCLA SARx: Los Angeles Addiction Specialists for Meth, Alcohol, Tobacco

Create your Like Badge

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

Study of Medical Treatment for Meth Addiction

noreply@blogger.com (Maria Sipin) — Wed, 07 Dec 2011 01:01:00 +0000

Interested in participating in a Los Angeles research study involving a medication for meth addiction?

The purpose of this clinical study is to find out if a medication can help people stop using meth and to determine if genetics influences a person's response to the medication.

Click the flyer to read more details or call the clinic at (866) 449-8252 for questions and appointments.

Other health care providers may refer patients to our program.

UCLA SARx Researcher Collaborates on New Medication for Meth

noreply@blogger.com (UCLA SARx) — Sun, 04 Dec 2011 01:23:00 +0000

UCLA SARx researcher Dr. Steven Shoptaw collaborated with San Francisco researchers on new study that may lead to medications to treat methamphetamine addiction. Info and links below.

In a double-blind, randomized, controlled, 12-week trial of mirtazapine vs placebo added to weekly substance use counseling, Colfax et al found that mirtazapine decreased methamphetamine use among methamphetamine-dependent, actively using men who had sex with men at high risk for acquiring or transmitting human immunodeficiency virus. Participants assigned to mirtazapine had significantly fewer methamphetamine-positive urine test results compared with participants assigned to placebo; sexual risk behavior also decreased more in the mirtazapine arm.

If you have questions or comments-- post below, e-mail us or send a message via http://twitter.com/uclasarx! We welcome your feedback! Thanks for tuning in.

New Meth Research Study Results Released.

noreply@blogger.com (UCLA SARx) — Sat, 03 Dec 2011 01:03:00 +0000

Press release from the journal Addiction on new research findings from study involving UCLA SARx researchers:

14 November 2011

A recent study has found that PROMETA™, a popular but controversial treatment for methamphetamine addiction, is no more effective than placebo in reducing methamphetamine use, keeping users in treatment, or reducing cravings for methamphetamine. The study was funded by Hythiam, the company that owns the PROMETA™ protocol, and is published online today in the scientific journal Addiction.

Methamphetamine, also known as meth, crystal meth, or ice, is the second most abused illicit drug in the world (cannabis is first), with 15-16 million regular users. The United States saw a rapid growth in methamphetamine addiction in the early 2000s. It was during that epidemic that PROMETA™ burst onto the public scene through an aggressive marketing campaign.

Since its introduction, the PROMETA™ protocol has been widely used in specialized private clinics in the U.S. as a treatment for methamphetamine addiction without going through the normal drug approval process. Normally, introducing a new medication requires approval by the U.S. Food and Drug Administration, including tests of product safety and a clinical trial to make sure the treatment produces the predicted effects. A loophole in this regulatory system allows a combination of previously approved medications to be marketed without review, whether or not the individual medications were originally approved as a treatment for the condition the new protocol targets. The manufacturer of PROMETA™, Hythiam, was therefore able to market and sell the new protocol with no federal review or clinical trial evidence.

Private patients reportedly pay $12,000 to $15,000 for one month of treatment.

Hythiam used some of its profits to fund the clinical trials long called for by the scientific community, including this one, designed and led by Dr. Walter Ling, a respected U.S. scientist and expert on methamphetamine addiction. Ling and his fellow researchers found that the group of participants given the PROMETA™ treatment did not have better outcomes than those given placebo in terms of reducing methamphetamine use, retention in treatment, or reducing methamphetamine cravings.

For more info on this research paper visit the Addiction Journal.

If you have questions or comments-- post below, e-mail us or send a message via http://twitter.com/uclasarx! We welcome your feedback! Thanks for tuning in.

AIDS 2012 Brown Bag Webinar Series

noreply@blogger.com (Maria Sipin) — Mon, 21 Nov 2011 17:42:00 +0000

HIV and Drug Use Fellowship

noreply@blogger.com (Maria Sipin) — Thu, 03 Nov 2011 16:18:00 +0000

Application period for the HIV and Drug Use Fellowship is December 8, 2011 to February 10, 2012. Visit the International AIDS Society official website for more information.

Webcast on Methamphetamine Neurotoxicity

noreply@blogger.com (UCLA SARx) — Thu, 06 Oct 2011 20:26:00 +0000

Not something we have done but looks good so I thought I'd pass it along!

Looks like it will be an interesting and informative lecture from the University of Florida and NIDA on meth and neurotoxicity. Info below (I believe it is EASTERN TIME but check their website!):

University of Florida

Departments of Psychiatry & Neurology Grand Rounds:
"Methamphetamine Neurotoxicity: Myths and Realities"

Jean Lud Cadet, MD

Chief, Molecular Neuropsychiatry Research Branch
Associate Director for Diversity and Outreach
NIH/NIDA Intramural Research Program
Baltimore, MD

DATE: Friday, October 7, 2011

TIME: 2:00 - 3:00 PM

Watch Live here: http://psychiatry.ufl.edu/grandrounds/cadet.htm

McKnight Brain Institute
DeWeese Auditorium

Goals and Objectives:
1. Learn about the epidemiology and clinical manifestations of methamphetamine abuse disorders
2. Understand the effects of methamphetamine on dopamine systems
3. Learn the toxic effects of methamphetamine on the brain
4. Understand the molecular bases of methamphetamine-induced changes in the brain.

For further information, please visit : http://psychiatry.ufl.edu/GrandRounds/
If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

Meth Trends and Quest Diagnostics Drug Testing Index 2011

noreply@blogger.com (Maria Sipin) — Wed, 05 Oct 2011 19:29:00 +0000

QuestDiagosticsTV interviews in this video discuss U.S. worker drug use and findings from Quest Diagnostics annual report released in September. The Quest Diagnostics Drug Testing Index™ includes an analysis of methamphetamine positives based on more than 4.5 million urine specimens collected in 2010.

Barry Sample PhD
Director of Science & Technology, Quest Diagnostics Employer Solutions:

"In the last year thousands of U.S. workers have tested positive for methamphetamine."
"What the public and employers need to understand is that methamphetamine is a highly addictive stimulant drug."

Steven Shoptaw PhD
Professor and NIDA Funded Researcher, UCLA:

"The importance of these data from Quest Diagnostics is that this is the largest sample of drug testing results from the workplace. One of the new things that came out of the data though is that there does appear to be an advancement into states where maybe it's not been such a problem before."
"This is about brain disease. We need to look at our data, get smarter about making available to the people who need treatment, options that will help them meet their goals."
"It makes great sense to me that we should do everything we can to stop people from trying this drug even once."
"Once you have a positive result you have some information that lets you know that your employee's in trouble in some way."

John Senego
Adoptive father & author, My Three Sons: The Birth of a New Family

"The immediate impact on an employer is that it's going to affect productivity in the workplace and so they have the right to be concerned about that and to test for that reason."

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

Exercise changes your brain and may help you kick meth

noreply@blogger.com (UCLA SARx) — Sat, 01 Oct 2011 04:41:00 +0000

Exercise has a variety of physical health benefits that are well established. Now there are increasing research reports regarding the potential benefits of exercise for mental health. In a recent study, O'Dell and colleagues found that exercising rats (by having them run on a wheel) actually reduces methamphetamine-induced damage to the dopamine and serotonin systems in the brain. There may be a biological mechanism behind the beneficial effects of exercise on mental health. In particular, other research has suggested that brain growth factors, such as BDNF, are increased by exercise.

So when can we get one of the TV exercise guru's to turn their attention to helping patients beat addiction in addition to losing weight? PS- make sure to talk to your doctor to make sure you are fit enough for exercise before beginning any exercise regimen and also start low and go slow so as not to injure yourself!

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

The Importance of Starting Strong in Addiction Treatment

noreply@blogger.com (UCLA SARx Contributor) — Fri, 09 Sep 2011 22:21:00 +0000

Hi there... Dr. Brensilver here. In clinical trials of addiction treatments, the main interest is in end-of-trial drug abstinence. Researchers try to understand if a particular treatment helps people establish abstinence during the last two weeks of treatment and during the follow-up period. Of course, in these last two weeks, some people are clean and some people are not. It is an important scientific question why some can achieve abstinence and some cannot. Many studies have examined the behavioral and biological factors that are linked to better outcomes. For example, people who are using methamphetamine on a daily basis find it much more difficult to quit than those who use every other day. People who show more dysfunction in the brain’s reward system also have more trouble getting clean. More recently, research has examined the importance of early treatment response (getting abstinent in the first two weeks) for understanding why some people end up clean, and some continue to use. When trying to quit cigarettes, establishing abstinence in the first two weeks is especially important. The people who have success at the very beginning of treatment are way more likely to be abstinent at the end of the trial and in the year after the trial. Similar results have been found for cocaine. In our research with people addicted to methamphetamine, the same pattern is appearing. Now, it’s important to say that we don’t know if early success causes people to quit long-term. It’s possible that early abstinence and long-term success are both effects of some other factor or combination of factors. Instead, we say that early abstinence is a marker for later success. So, the upshot of all this: it’s important to start strong. Making a clear commitment and doing one’s best to implement a treatment plan is key. And if people can weather the initial storm, when withdrawal effects are strongest, then they have a much better chance of staying clean.

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

Addiction is a "chronic brain disorder" per new ASAM definition

noreply@blogger.com (UCLA SARx) — Wed, 17 Aug 2011 17:11:00 +0000

Hello. Dr. Heinzerling here. News from the American Society of Addiction Medicine. They recently released a revised definition of addiction (press release)! The new definition describes addiction as:

"a chronic brain disorder and not simply a behavioral problem involving too much alcohol, drugs, gambling or sex."

It's hard not to ask what took them so long to come to this conclusion, given the volumes of scientific research on this topic that has accumulated over the past 30 years, but I guess better late than never!

After a quick review of the new definition (you can check out the details of the definition for yourself here) I have a few thoughts. First, I think the definition does a decent job of including both biological and psycho-social aspects of addiction. In addition, they present the following handy rubric (maybe they should call it the A, B, C, D, E's of addiction), to describe addiction:

Addiction is characterized by:
   a. Inability to consistently Abstain;
   b. Impairment in Behavioral control;
   c. Craving; or increased “hunger” for drugs or rewarding experiences;
   d. Diminished recognition of significant problems with one’s behaviors and interpersonal relationships; and
   e. A dysfunctional Emotional response.

Another E they include is the power of external cues. They make the point that this rubric should not be used as a means of clinically diagnosing patients with addiction (wait for the DSM-V for that!) but I think it is handy and relatively easy to remember and could be a great teaching tool for medical students and residents to remember some important clinical characteristics that accompany addiction.

Anyway, you may be asking what difference does this new definition of addiction make? Well first it has generated some press and attention and interest in the topic which can never hurt, particularly when it is highlighting the biological aspects of addiction. But frankly it probably won't change much outside of ASAM. Still I would consider it an important step for ASAM in acknowledging the important role that biology does play in drug addiction, while continuing to recognize the importance of non-biological factors as well, as ASAM has not always been up to speed on the biological side in the past (not meant to be a criticism, just my opinion). So good work ASAM and keep it up.

Well, let us know what you think of the new definition and/or our take on it. If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

Follow Meth 101 on Twitter

noreply@blogger.com (UCLA SARx) — Tue, 16 Aug 2011 21:47:00 +0000

We want you to know we'll be posting news related to meth addiction and treatment research on our Twitter feed (uclasarx). So follow us on Twitter and search #Meth_101 to see our meth news posts!

If you have questions or comments-- post below, e-mail us or send a message via Twitter @UCLASARx! We welcome your feedback! Thanks for tuning in.

Los Angeles Addiction Treatment & Clinical Research at UCLA SARx

Social Networks and Drug Cues Presentation Abstract Online

Picutres/video from today's presentation in HIV and Meth Addiction

Exposure to Drug-related ‘People, Places, and Things’ via Online Social Networking Sites among Adolescents in Substance Abuse Treatment

NEW UCLA SARx METH STUDY PUBLISHED

Baseline Findings from the HPTN 061 BROTHERS Project: Participant Characteristics

Just say no?

High Dose Opioids for Pain and Overdose Risk

New UCLA SARx study published on differences in meth use between men and women

Cocaine and amphetamine positive tests increase in the workplace.

Conference: Preventing HIV, Hepatitis, & Tuberculosis Among Substance-Using Populations

Addiction Medicine Fellowship- Primary Care Doctors!!

New UCLA SARx Meth Research Published

Check out the new METH section of our website

UCLA SARx on Facebook

Study of Medical Treatment for Meth Addiction

UCLA SARx Researcher Collaborates on New Medication for Meth

New Meth Research Study Results Released.

14 November 2011

AIDS 2012 Brown Bag Webinar Series

HIV and Drug Use Fellowship

Webcast on Methamphetamine Neurotoxicity

University of Florida

Departments of Psychiatry & Neurology Grand Rounds:"Methamphetamine Neurotoxicity: Myths and Realities"

Jean Lud Cadet, MD

DATE: Friday, October 7, 2011

TIME: 2:00 - 3:00 PM

Watch Live here: http://psychiatry.ufl.edu/grandrounds/cadet.htm

McKnight Brain InstituteDeWeese Auditorium

Meth Trends and Quest Diagnostics Drug Testing Index 2011

Exercise changes your brain and may help you kick meth

The Importance of Starting Strong in Addiction Treatment

Addiction is a "chronic brain disorder" per new ASAM definition

Follow Meth 101 on Twitter

Departments of Psychiatry & Neurology Grand Rounds:
"Methamphetamine Neurotoxicity: Myths and Realities"

McKnight Brain Institute
DeWeese Auditorium